Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Short Bowel Syndrome (SBS) was valued at US$2 Billion in 2024 and is projected to reach US$6 ...

In this cohort of patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use was associated with significantly lower risks of vertebral compression fractures and related ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

In 2025, the line between brand messaging and cultural commentary continued to blur. As the year ends, let’s look back at the ...

Losing weight can be an important part of managing diabetes. Diabetes is a condition that affects how your body processes glucose (sugar). Your body either doesn’t produce enough insulin (a hormone ...

The study analyzed electronic health records from 708,406 patients diagnosed with breast cancer between January 2011 and ...

Biocon launches its glucagon-like peptide-1, liraglutide in Netherlands: Our Bureau, Bengaluru Monday, December 15, 2025, 13:30 Hrs [IST] Biocon has launch of its GLP-1 peptide, l ...

Loss of muscle mass, also called muscle wasting or atrophy, can happen gradually as part of getting older or more suddenly ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...